Equities

Azenta Inc

Azenta Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)45.58
  • Today's Change0.42 / 0.93%
  • Shares traded1.46m
  • 1 Year change-20.95%
  • Beta1.4891
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

  • Revenue in USD (TTM)656.32m
  • Net income in USD-164.17m
  • Incorporated1994
  • Employees3.30k
  • Location
    Azenta Inc200 Summit Drive, 6Th FloorBURLINGTON 01803United StatesUSA
  • Phone+1 (978) 262-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.azenta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Structure Therapeutics Inc (ADR)0.00-110.55m1.91bn148.00--2.13-----2.21-2.210.0015.660.00----0.00-19.23---20.17--------------0.00-------69.62------
Disc Medicine Inc0.00-103.48m1.93bn74.00--4.13-----3.97-3.970.0015.730.00----0.00-23.74---24.88--------------0.00-------63.22------
Beam Therapeutics Inc349.64m-143.59m2.07bn436.00--2.61--5.93-1.72-1.724.279.580.284----801,933.50-11.67-24.54-13.84-29.26-----41.07-211.96----0.00--520.01--54.16--20.78--
Wave Life Sciences Ltd53.61m-142.52m2.08bn266.00--14.95--38.76-1.11-1.110.4271.010.192--15.32201,541.40-51.04-56.98-99.07-102.38-----265.84-353.20----0.00--3,005.1051.0464.46---35.44--
Mirum Pharmaceuticals Inc307.03m-99.81m2.13bn311.00--9.25--6.95-2.12-2.126.514.840.46573.835.281,162,985.00-15.14-38.93-17.70-44.8872.68---32.51-190.713.15--0.5701--141.85---20.45--21.81--
Azenta Inc656.32m-164.17m2.21bn3.30k--1.16--3.37-2.97-2.9712.3138.820.26333.233.71---6.59-2.07-7.18-2.3140.1343.11-25.01-8.763.50-------1.32-3.41-1,174.32------
CG Oncology Inc684.00k-78.29m2.25bn61.00--4.21--3,282.26-1.19-1.190.01047.950.0018--9.9111,213.12-18.93---19.63-------10,578.22------0.00--6.81---54.83------
Keros Therapeutics Inc651.00k-181.57m2.27bn160.00--4.12--3,479.53-5.21-5.210.018713.570.0014----4,786.77-40.10-35.95-42.23-38.07-----27,890.94-1,237.26----0.00-----56.77-46.15--62.57--
Akero Therapeutics Inc0.00-237.22m2.28bn60.00--3.09-----3.75-3.750.0010.610.00----0.00-32.66-37.73-34.35-40.13------------0.0454-------35.46------
Arrowhead Pharmaceuticals Inc19.65m-538.64m2.30bn525.00--6.97--117.30-4.65-4.650.17012.660.0234----37,424.76-65.18-20.02-73.62-24.65-----2,785.85-61.79---154.930.00---1.0371.68-16.59--162.38--
Ideaya Biosciences Inc3.92m-178.12m2.32bn124.00--1.96--590.39-2.32-2.320.051513.670.0044--1.1731,629.03-20.09-19.17-20.87-21.05-----4,541.56-244.55----0.00---54.08---92.59--6.75--
Longboard Pharmaceuticals Inc0.00-76.34m2.33bn50.00--8.48-----2.24-2.240.007.050.00----0.00-42.91---46.16--------------0.00-------23.84------
Belite Bio Inc (ADR)0.00-33.03m2.46bn20.00--22.08-----1.11-1.110.003.630.00----0.00-38.10---38.10--------------0.00-------150.09------
Geron Corp29.48m-201.19m2.46bn141.00--8.40--83.46-0.3221-0.32210.04690.48460.0687--1.31209,078.00-46.90-51.32-63.81-64.9097.29---682.47-19,949.132.74--0.2229---60.23-25.97-29.76--120.29--
Soleno Therapeutics Inc0.00-131.16m2.49bn33.00--8.96-----3.31-3.310.006.450.00----0.00-72.82-53.90-82.94-61.85------------0.00-------62.00------
Data as of Nov 25 2024. Currency figures normalised to Azenta Inc's reporting currency: US Dollar USD

Institutional shareholders

51.27%Per cent of shares held by top holders
HolderShares% Held
Politan Capital Management LPas of 06 Nov 20244.61m9.43%
The Vanguard Group, Inc.as of 30 Sep 20244.60m9.41%
BlackRock Fund Advisorsas of 30 Sep 20244.03m8.24%
Dimensional Fund Advisors LPas of 30 Sep 20242.86m5.86%
Kayne Anderson Rudnick Investment Management LLCas of 30 Sep 20242.28m4.66%
SSgA Funds Management, Inc.as of 30 Sep 20241.69m3.45%
GW&K Investment Management LLCas of 30 Sep 20241.56m3.18%
Allspring Global Investments LLCas of 30 Sep 20241.30m2.65%
Teacher Retirement System of Texasas of 30 Sep 20241.10m2.26%
Macquarie Investment Management Business Trustas of 30 Sep 20241.05m2.14%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.